Evidence map›Paper›PMID 40493404›Full record

ArticleThe Journal of clinical investigation2025

Wilms tumor 1 impairs apoptotic clearance of fibroblasts in distal fibrotic lung lesions.

Harshavardhana H Ediga, Chanukya P Vemulapalli, Vishwaraj Sontake, Pradeep K Patel, Hikaru Miyazaki, Dimitry Popov, Martin B Jensen, Anil G Jegga, Steven K Huang, Christoph Englert and 4 more

Abstract read
In one paragraph

Article in The Journal of clinical investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Harshavardhana H EdigaDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Chanukya P VemulapalliDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Vishwaraj SontakeGordian Biotechnology, South San Francisco, California, USA.
Pradeep K PatelDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Hikaru MiyazakiGordian Biotechnology, South San Francisco, California, USA.
Dimitry PopovGordian Biotechnology, South San Francisco, California, USA.
Martin B JensenGordian Biotechnology, South San Francisco, California, USA.
Anil G JeggaDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Steven K HuangDivision of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Christoph EnglertMolecular Genetics Lab, Leibniz Institute on Aging - Fritz Lipmann Institute, Jena, Germany.
Andreas SchedlInstitute of Biology Valrose, University of Sophia-Antipolis, Nice, France.
Nishant GuptaDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Francis X McCormackDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Satish K MadalaDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of Cincinnati, Cincinnati, Ohio, USA.

Funding

The Role of KCNMB1 and the Large Conductance Potassium (BK) Channel in Myofibroblast Differentiation and Pulmonary FibrosisR01HL127203 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI HUANG, STEVEN K · 2015 to 2024
$4.4M
WT1 REGULATION OF PULMONARY FIBROSISR01HL134801 · NHLBI · UNIVERSITY OF CINCINNATI · PI MADALA, SATISH K · 2017 to 2025
$3.9M
Heterogeneity and Regulation of the DNA Methylome in IPF Mesenchymal CellsR01HL162963 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STEVEN K HUANG · 2023 to 2026
$2.7M
Sox9 Regulation of Fibroblast Activation and Pulmonary FibrosisR01HL157176 · NHLBI · UNIVERSITY OF CINCINNATI · PI MADALA, SATISH K · 2021 to 2025
$2.5M
NHLBI NIH HHS R01 HL127203NHLBI NIH HHS R01 HL134801NHLBI NIH HHS R01 HL157176NHLBI NIH HHS R01 HL162963
6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic lung disease characterized by impaired fibroblast clearance and excessive extracellular matrix (ECM) protein production. Wilms tumor 1 (WT1), a transcription factor, is selectively upregulated in IPF fibroblasts. However, the mechanisms by which WT1 contributes to fibroblast accumulation and ECM production remain unknown. Here, we investigated the heterogeneity of WT1-expressing mesenchymal cells using single-nucleus RNA-Seq of distal lung tissues from patients with IPF and control donors. WT1 was selectively upregulated in a subset of IPF fibroblasts that coexpressed several prosurvival and ECM genes. The results of both loss-of-function and gain-of-function studies were consistent with a role for WT1 as a positive regulator of prosurvival genes to impair apoptotic clearance and promote ECM production. Fibroblast-specific overexpression of WT1 augmented fibroproliferation, myofibroblast accumulation, and ECM production during bleomycin-induced pulmonary fibrosis in young and aged mice. Together, these findings suggest that targeting WT1 is a promising strategy for attenuating fibroblast expansion and ECM production during fibrogenesis.

Indexed as

ApoptosisFibroblastsIdiopathic Pulmonary FibrosisLungWT1 ProteinsAnimalsBleomycinExtracellular MatrixFemaleHumansMaleMiceBleomycinWT1 protein, humanWT1 protein, mouseWT1 ProteinsApoptosisExtracellular matrixFibrosisInflammationPulmonology

Identifiers

PMID40493404
PMCPMC12321392

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.